

2020 年度

学会発表(国内学会)

2020.06 第 24 回腸内細菌学会学術集会(誌上開催)

1. 胃がん患者を対象とした腸内細菌叢の大規模臨床研究における採便に関するアンケート調査.
砂川 優, 的場 亮, 佐藤 慶治, 西山 光恵, 森原 元彦, 寺内 淳, 市川 度, 藤井 雅志.

2020.08 JASCC 緩和・支持・心のケア 合同学術大会

1. 「がんと診断されたときからの緩和ケア」の推進に関わる厚生労働行政への提言の策定.
采野 優, 堀江 良樹, 森田 達也, 内藤 明美, 小山田 隼佑, 陶山 久司, 小島 康幸, 野里 洵子, 森 雅紀,
中島 貴子, 清水 千佳子, 恒藤 暁, 武藤 学.
2. がん診断時からの緩和ケアを提供するための患者のアンメットニーズに関する研究.
内藤 明美, 采野 優, 森田 達也, 堀江 良樹, 小山田 隼佑, 野里 洵子, 小島 康幸, 陶山 久司, 森 雅紀,
中島 貴子, 清水 千佳子, 恒藤 暁, 武藤 学.

2020.08 第 106 回日本消化器病学会総会

1. 大腸癌化学療法～Basic and New～.
中島 貴子.

2019.01 第 24 回日本緩和医療学会学術集会

1. 血管新生阻害薬による化学療法中に下腸間膜動静脈瘻を合併した大腸癌症例.
土井 綾子, 近江 亮介, 梅本 久美子, 新井 裕之, 伊澤 直樹, 小倉 孝氏, 津田 享志, 中島 貴子.

2020.11 第 58 回日本癌治療学会学術集会

1. 高齢者胃癌に対する治療の工夫.
Doi Ayako, Takeda Hiroyuki, Umemoto Kumiko, Arai Hiroyuki, Horie Yoshiki, Mizukami Takuro, Izawa Naoki, Ogura Takashi, Oguri Tomoyo, Sunakawa Yu.
2. Multi-gene panel testing in patients with gastro-intestinal cancers: A retrospective study.
Takeda Hiroyuki, Imoto Kiyomi, Umemoto Kumiko, Doi Ayako, Arai Hiroyuki, Horie Yoshiki, Mizukami Takuro,
Izawa Naoki, Ogura Takashi, Oguri Tomoyo, Sunakawa Yu.

2020.11 第 17 回 DIA 日本年会 2020

1. Practical situations of the clinical trial using digital scales and devices.
水上 拓郎.

2021.02 第 18 回日本臨床腫瘍学会学術集会

1. Anti-VEGF inhibitors and Renal Safety in Onco-Nephrology consortium –Urinary Protein/Creatinine ratio [VERSION UP study].
M. Nakamura, T. Funakoshi, S. Kataoka, T. Horimatsu, Y. Nishikawa, T. Matsubara, T. Mizukami, T. Goto, K. Tsuchihashi, E. Baba, T. Tsumura, Y. Mihara, T. Hamaguchi, M. Yanagita, M. Muto.

2. 進行固形がん患者における免疫チェックポイント阻害薬導入前の抗体検査と免疫関連有害事象との関連性。
塩川 尚恵、伊澤 直樹、森川 慶、大橋 洋之、早川 望、春日井 滋、武田 弘幸、梅本 久美子、新井 裕之、土井 綾子、堀江 良樹、平川 麻美、水上 拓郎、小栗 知世、小倉 孝氏、田中 恒明、砂川 優。

3. Gene profiling of circulating tumor DNA (ctDNA) in RAS wild-type mCRC patients who are refractory to anti-EGFR antibody.
Naoki Izawa, Kazuto Nishio, Toshiki Masuishi, Naoki Takahashi, Hirokazu Shoji, Yoshiyuki Yamamoto, Toshihiko Matsumoto, Keiji Sugiyama, Takeshi Kajiwara, Hiroyuki Okuda, Naoki Aomatsu, Hisato Kawakami, Taito Esaki, Yukiya Narita, Hiroki Hara, Yu Sunakawa, Narikazu Boku, Toshikazu Moriwaki, Takako Eguchi Nakajima, and Kei Muro.

4. A phase I/II trial of trifluridine/tipiracil in combination with irinotecan in patients with advanced gastric cancer refractory to fluoropyrimidine, platinum, and taxane.
Tomohiro Nishina, Takuro Mizukami, Keiko Minashi, Hiroki Hara, Yusuke Amanuma, Naoki Takahashi, Akio Nakashima, Masaki Takahashi, Takako Eguchi Nakajima.

2021.03 第 93 回日本胃癌学会総会

1. Bi-weekly nab-paclitaxel and ramucirumab therapy for advanced gastric cancer: JACCRO GC-09 trial.
Naoki Izawa, Mitsugu Kochi, Shigenori Kadowaki, Ryohei Kawabata, Takao Takahashi, Akihito Tsuji, Hiroki Hara, Masato Nakamura, Toshikazu Moriwaki, Yu Sunakawa, Wataru Ichikawa, and Masashi Fujii.
2. TAS-118 plus oxaliplatin as perioperative chemotherapy in gastric cancer (APOLLO-11).
Takuro Mizukami, Daisuke Takahashi, Atsuo Takahashi, Naoki Ishizuka, Manabu Ohashi, Hitoshi Katai, Shinya Mikami, Takeshi Sano, Narikazu Boku, Kensei Yamaguchi.

学会発表(国際学会)

2020.05 ASCO 2020 Virtual

1. A basket trial of trastuzumab deruxtecan, a HER2-targeted antibody-drug conjugate, for HER2-amplified solid tumors identified by circulating tumor DNA analysis (HERALD trial).
Masataka Yagisawa, Yoshiaki Nakamura, Takayuki Yoshino, Yoshito Komatsu, Shigenori Kadowaki, Kei Muro, Yu Sunakawa, Taroh Satoh, Tomohiro Nishina, Taito Esaki, Satoshi Fujii, Hiromi Ono, Daiki Tomita, Noriko Fujishiro, Nami Hirano, Nozomu Fuse, Akihiro Sato, Gakuto Ogawa, Shogo Nomura, Hiroya Taniguchi.

2. Tumor response and growth rate of nivolumab treatment in advanced gastric cancer: real-world data from a large observational/translational study, JACCRO GC-08 (DELIVER trial).
Ryohei Kawabata, Yasuhiro Sakamoto, Eisuke Inoue, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masazumi Takahashi, Jin Matsuyama, Hiroshi Yabusaki, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Hisato Kawakami, Ryo Matoba, Kei Muro, Takako Eguchi Nakajima, Wataru Ichikawa, Masashi Fujii, and Yu Sunakawa.

3. Utility of circulating tumor DNA (ctDNA) versus tumor tissue genotyping for enrollment of patients with metastatic colorectal cancer (mCRC) to matched clinical trials: SCRUM–Japan GI–SCREEN and GOZILA combined analysis.

Yoshiaki Nakamura, Hiroya Taniguchi, Hideaki Bando, Taito Esaki, Yoshito Komatsu, Ken Kato, Naoki Takahashi, Yoshinori Kagawa, Takeshi Kato, Tomohiro Nishina, Taroh Satoh, Eiji Oki, Yu Sunakawa, Manabu Shiozawa, Yoshiyuki Yamamoto, Hisato Kawakami, Tadamichi Denda, Atsushi Ohtsu, Takayuki Yoshino.

4. Phase II trial of adjuvant mFOLFOX6 after metastasectomy for pulmonary metastasis of colorectal cancer: WJOG5810G.

Nozomu Machida, Takehiro Okumura, Junji Kishimoto, Narikazu Boku, Tomohiro Nishina, Koichi Suyama, Yasuhisa Ohde, Katsunori Shinozaki, Hideo Baba, Shinya Tokunaga, Hisato Kawakami, Takashi Tsuda, Masahito Kotaka, Hiroyuki Okuda, Hisateru Yasui, Tadamichi Denda, Kentaro Yamazaki, Shuichi Hironaka, Kei Muro, Ichinosuke Hyodo.

2020.05 92nd Annual Meeting of the Japanese Gastric Cancer Association

1. Feasibility of TAS–118+oxsliplation as perioperaive chemotherapy for gastric cancer.

Takahari Daisuke, Takashima Atsuto, Nakajima Takako, Ohashi Manabu, Mikami Shinya, Ishizuka Naoki.

2020.07 WCGC Virtual

1. Updated analysis of DELIVER trial (JACCRO GC–08): A large observational/translational study of nivolumab treatment in advanced gastric cancer.

Yu Sunakawa, Yasuhiro Sakamoto, Eisuke Inoue, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masazumi Takahashi, Jin Matsuyama, Hiroshi Yabusaki, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Naoki Hirabayashi, Atsushi Takeno, Hisato Kawakami, Ryo Matoba, Kei Muro, Takako Eguchi Nakajima, Wataru Ichikawa, and Masashi Fujii.

2020.09 ESMO VIRTUAL CONGRESS

1. 104P Angiogenesis–related factors and clinical outcomes in combination therapy with paclitaxel (PTX), ramucirumab (RAM) plus nivolumab (Nivo) for advanced gastric cancer (AGC).

Naoki Izawa, Shigeki Ohta, Shigenori Kadowaki, Takeshi Kajiwara, Keiko Minashi, Yu Sunakawa, Kei Muro, Tomohiro Nishina, Shuichi Hironaka, Takeharu Yamanaka, Takako Eguchi Nakajima, Yutaka Kawakami.

2020.11 ESMO ASIA

1. Anti–VEGF inhibitors and Renal Safety in Onco–Nephrology consortium –Urinary Protein/Creatinine ratio [VERSiON UP study].

M. Nakamura, T. Funakoshi, S. Kataoka, T. Horimatsu, Y. Nishikawa, T. Matsubara, T. Mizukami, T. Goto, K. Tsuchihashi, E. Baba, T. Tsumura, Y. Mihara, T. Hamaguchi, M. Yanagita, M. Muto.

1. Efficacy of chemotherapy for patients with unresectable or recurrent pancreatic adenocarcinoma: A multicenter retrospective analysis.
Yukio Yoshida, Akira Fukutomi, Makoto Ueno, Keita Mori, Kazuo Watanabe, Akihiro Ohba, Satoshi Kobayashi, Mitsuhiro Furuta, Akiko Tsujimoto, Masato Osaka, Naohiro Okano, Kei Yane, Kumiko Umemoto, Yasuyuki Kawamoto, Takeshi Terashima, Hidetaka Tsumura, Keitaro Doi, Kazuhiko Shioji, Akinori Asagi, Junji Furuse.
2. Feasibility study of TAS-118 plus oxaliplatin as perioperative chemotherapy for patients with advanced gastric cancer (APOLLO-11).
Takahari Daisuke, Ohashi Manabe, Takashima Atsuo, Mizukami Takuro, Ishizuka Naoki, Katai Hitoshi, Mikami Shinya, Wakatsuki Takeru, Chin Keisho, Ida Satoshi, Kumagai Koshi, Nunobe Souya, Iwasa Satoru, Ito Miki, Wada Takeyuki, Yamagata Yikinori, Ogura Takashi, Sano Takeshi, Boku Narikazu, Yamaguchi kensei.
3. Phase II study of systemic chemotherapy with S-1 plus oxaliplatin followed by surgery in patients with cT3-T4a and/or node-positive advanced adenocarcinoma of the esophagogastric junction; Primary endpoint results of the ESOX trial.
Imamura Yu, Chin Keisho, Tsushima Takahito, Tsubosa Yasuhiro, Hara Hiroki, Fukuda Takashi, Nomura Motoo, Tsunoda Shigeru, Ogata Takashi, Hayashi Tsutomu, Nabeya Yoshihiro, Minashi Keiko, Kuramochi Hidekazu, Hamano Mie, Doi Ayako, Mikami Shinya, Mine Shinji, Isizuka Naoki, Ichimura Takashi.
4. A translational study to evaluate genomic markers and concordance with circulating-tumor DNA and circulating tumor cells to predict clinical outcomes in gastrointestinal and pancreatobiliary cancers: Valor trial.
Ayako Doi, Kumiko Umemoto, Tomoyo Oguri, Hiroyuki Takeda, Yoshiki Horie, Takashi Ogura, Takuro Mizukami, Naoki Izawa, Sungmok Jung, Byung Chul Kim, Yu Sunakawa.
5. A phase I/II trial of trifluridine/tipiracil in combination with irinotecan in patients with advanced gastric cancer refractory to fluoropyrimidine, platinum, and taxane.
Hiroki Hara, Takuro Mizukami, Keiko Minashi, Tomohiro Nishina, Naoki Takahashi, Yusuke Amanuma, Akio Nakashima, Masaki Takahashi, Takako Eguchi Nakajima.
6. Genomic pathway of gut microbiome to predict efficacy of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08).
Yu Sunakawa, Ryo Matoba, Eisuke Inoue, Yoshikazu Takahashi, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masazumi Takahashi, Jin Matsuyama, Hiroshi Yabusaki, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Hisato Kawakami, Kei Muro, Takako Eguchi Nakajima, Wataru Ichikawa, and Masashi Fujii.

論文業績(和文)

《原著・総説・解説》

1. 上部消化管がん治療 State of the art.

- 腫瘍内科, 25(6)604-12.
- 伊澤 直樹, 中島 貴子.

2. 消化器がんの病態と治療

- 消化器ナーシング, 2020年5月号.
- 水上 拓郎.

3. 胃がん一次治療 HER2 以外の分子標的薬の開発

- オンコロジークリニカルガイド.
- 水上 拓郎

4. ラムシルマブ、下痢

- YORi-SOU がんナーシング, 2020.
- 伊澤 直樹、小倉 孝氏.

5. 診断時からの緩和ケア—本当の意味

- 医学のあゆみ, 274(8): 655-659.
- 堀江 良樹.

6. 口内炎、下痢・便秘、嘔吐・悪心、味覚障害.

- Clinical nursing Skills ひとりだちできる がん化学療法看護, 2021
- 伊澤 直樹.

7. 大腸癌三次治療以降.

- オンコロジークリニカルガイド 消化器癌化学療法改定 5 版, 2021;5:280-287.
- 伊澤直樹.

8. がんナーシング 別冊.

- がん化学療法の薬はや調べノート 2020・2021 年版改定 5 版, 70-71.
- 伊澤 直樹, 小倉 孝氏.
- がん化学療法の薬はや調べノート 2020・2021 年版改定 5 版, 168-175.
- 新井裕之、中島貴子.

9. パクラムニボ論文の英訳と監修.

- 消化器病の広場, 2021
- 伊澤 直樹、武田 弘幸.

《原著・総説》

1. Recent Developments of Systemic Chemotherapy for Gastric Cancer.

 - Cancers (Basel). 12(5):1100, 2020.
 - Hiroyuki Arai, Takako Eguchi Nakajima.

2. The potential application of PD-1 blockade therapy for early-stage biliary tract cancer.

 - International Immunology. 32(4):273-281, 2020.
 - Kumiko Umemoto, Yosuke Togashi, Yasuhito Arai, Hiromi Nakamura, Shinichiro Takahashi, Tokiyoshi Tanegashima, Mikiya Kato, Tsubasa Nishikawa, Daisuke Sugiyama, Motohiro Kojima, Naoto Gotohda, Takeshi Kuwata, Masafumi Ikeda, Tatsuhiro Shibata, Hiroyoshi Nishikawa.

3. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study).

 - International Journal of Clinical Oncology. 25(10):1835-1843, 2020.
 - Naohiro Okano, Chigusa Morizane, Shogo Nomura, Hideaki Takahashi, Hidetaka Tsumura, Hironaga Satake, Nobumasa Mizuno, Kunihiro Tsuji, Kazuhiko Shioji, Akinori Asagi, Kohichiroh Yasui, Sho Kitagawa, Tomomi Kashiwada, Atsushi Ishiguro, Masashi Kanai, Makoto Ueno, Takashi Ogura, Satoshi Shimizu, Tobimatsu Kazutoshi, Masayo Motoya, Koji Nakashima, Masafumi Ikeda, Takuji Okusaka, Junji Furuse.

4. Randomised Phase II Study of Panitumumab Plus Irinotecan Versus Cetuximab Plus Irinotecan in Patients With KRAS Wild-Type Metastatic Colorectal Cancer Refractory to Fluoropyrimidine, Irinotecan and Oxaliplatin (WJOG 6510G).

 - Eur J Cancer. 135:11-21, 2020.
 - Daisuke Sakai, Hiroya Taniguchi, Naotoshi Sugimoto, Takao Tamura, Tomohiro Nishina, Hiroki Hara, Taito Esaki, Tadamichi Denda, Takeshi Sakamoto, Hiroyuki Okuda, Taroh Satoh, Takahiro Tsushima, Akitaka Makiyama, Takashi Tsuda, Ayumu Hosokawa, Hidekazu Kuramochi, Shinya Tokunaga, Toshikazu Moriwaki, Hisateru Yasui, Hiroyasu Ishida, Akihito Tsuji, Satoshi Otsu, Hozumi Shimokawa, Eishi Baba, Mikio Sato, Shigemi Matsumoto, Yukinori Ozaki, Katsunori Shinozaki, Hiroshi Tamagawa, Masahiro Goto, Shigenori Kadowaki, Hirofumi Fujii, Yasuhiro Koh, Kentaro Yamazaki, Shuichi Hironaka, Junji Kishimoto, Narikazu Boku, Ichinosuke Hyodo, Kei Muro.

5. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).

 - Eur J Cancer. 38(17):1919-27, 2020.
 - Akitaka Makiyama, Yasutaka Sukawa, Tomomi Kashiwada, Junji Kawada, Ayumu Hosokawa, Yoshiki Horie, Akihito Tsuji, Toshikazu Moriwaki, Hiroaki Tanioka, Katsunori Shinozaki, Keita Uchino, Hirofumi Yasui, Hiroshi Tsukuda, Kazuhiro Nishikawa, Hiroyasu Ishida, Takeharu Yamanaka, Kentaro Yamazaki, Shuichi Hironaka, Taito Esaki, Narikazu Boku, Ichinosuke Hyodo, Kei Muro.

6. Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer.

 - Cancer Chemotherapy and Pharmacology. 86:277–284, 2020.
 - Yosuke Kito, Hironaga Satake, Hiroya Taniguchi, Takeshi Yamada, Yoshiki Horie, Taito Esaki, Tadamichi Denda, Hisateru Yasui, Naoki Izawa, Toshiki Masuishi, Toshikazu Moriwaki, Keita Mori, Kentaro Yamazaki.

7. Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer.

 - Investigational New Drugs. 38(2):410–418, 2020.
 - Takako Eguchi Nakajima, Narikazu Boku, Ayako Doi, Hiroyuki Arai, Takuro Mizukami, Yoshiki Horie, Naoki Izawa, Mami Hirakawa, Takashi Ogura, Takashi Tsuda, Yu Sunakawa.

8. RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal Cancer.

 - JCO precision oncology. 4(2020):898–911, 2020.
 - Yu Sunakawa, Kaoru Mogushi, Heinz-Josef Lenz, Wu Zhang, Akihito Tsuji, Takehiro Takahashi, Tadamichi Denda, Ken Shimada, Mitsugu Kochi, Masato Nakamura, Masahito Kotaka, Yoshihiko Segawa, Hiroaki Tanioka, Yuji Negoro, Miriana Moran, Stephanie H Astrow, Jack Hsiang, Craig Stephens, Masashi Fujii, Wataru Ichikawa.

9. Early tumor shrinkage and depth of response in the second-line treatment for KRAS exon2 wild-type metastatic colorectal cancer: An exploratory analysis of the randomized phase 2 trial comparing panitumumab and bevacizumab in combination with FOLFIRI (WJOG6210G).

 - Targeted Oncology. 2020(15):623–633, 2020.
 - Naoki Izawa, Kohei Shitara, Kimio Yonesaka, Takeharu Yamanaka, Takayuki Yoshino, Yu Sunakawa, Toshiki Masuishi, Tadamichi Denda, Kentaro Yamazaki, Toshikazu Moriwaki, Hiroyuki Okuda, Chihiro Kondoh, Tomohiro Nishina, Akitaka Makiyama, Hideo Baba, Hironori Yamaguchi, Masato Nakamura, Ichinosuke Hyodo, Kei Muro, Takako Eguchi Nakajima.

10. Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients.

 - Cancers (Basel). 2(10):2947, 2020.
 - Volz NB, Hanna DL, Stintzing S, Zhang W, Yang D, Cao S, Ning Y, Matsusaka S, Sunakawa Y, Berger MD, Cremolini C, Loupakis F, Falcone A, Lenz HJ.

11. Biomarker Analysis in A Randomized Phase 2 Study of Panitumumab Versus Cetuximab in Colorectal Cancer (WJOG6510GTR).

 - J Cancer Sci Clin Ther. 4(4):499–510, 2020.
 - Hiroya Taniguchi, Yasuhiro Koh, Naotoshi Sugimono, Tomohiro Nishina, Takao Tamura, Hiroki Hara, Taito Esaki, Tadamichi Denda, Akitaka Makiyama, Aya Sakai, Hiroyuki Okuda, Naoki Izawa, Takayuki Ando, Kentaro Yamazaki, Shinya Tokunaga, Toshikazu Moriwaki, Akihito Tsuji, Hidekazu Kuramochi, Katsunori Shinozaki, Yukinori Ozaki, Hironori Yamaguchi, Hisateru Yasui, Satoshi Otsu, Mio Ikeda, Junji Kishimoto, Taroh Satoh, Daisuke Sakai, Kei Muro.

12. Prospective evaluation and refinement of an S-1 dosage formula based on renal function for the clinical application.

- Cancer Science. 111(2):751–759, 2020.
- Takeuchi Masashi, Imamura Chiyo, Booka Eisuke, Takeuchi Hiroya, Mizukami Takuro, Kawakami Takeshi, Funakoshi Taro, Wakuda Kazushige, Aoki Yu, Hamamoto Yasuo, Kitago Minoru, Kawakubo Hirofumi, Boku Narikazu, Tanigawara Yusuke, Kitagawa Yuko.

13. Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer.

- Journal for Immunotherapy of Cancer. 8(2):e001714, 2020.
- Hiroyuki Arai, Yi Xiao, Fotios Loupakis, Natsuko Kawanishi, Jingyuan Wang, Francesca Battaglin, Shivani Soni, Wu Zhang, Christoph Mancao, Bodour Salhia, Shannon M Mumenthaler, Daniel J Weisenberger, Gangning Liang, Chiara Cremolini, Alfredo Falcone, Joshua Millstein, Heinz-Josef Lenz.

14. FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer.

- Cancer science. 112(1):314–322, 2020.
- Hasegawa Hiroko, Taniguchi Hiroya, Nakamura Yoshiaki, Kato Takeshi, Fujii Satoshi, Ebi Hiromichi, Shiozawa Manabu, Yuki Satoshi, Masuishi Toshiiki, Kato Ken, Izawa Naoki, Moriwaki Toshikazu, Oki Eiji, Kagawa Yoshinori, Denda Tadamichi, Nishina Tomohiro, Tsuji Akihito, Hara Hiroki, Esaki Taito, Nishida Naohiro, Kawakami Hisato, Sakamoto Yasumasa, Miki Izumi, Okamoto Wataru, Yamazaki Kentaro, Yoshino Takayuki.

15. The impact of ARID1A mutation on molecular characteristics in colorectal cancer.

- Eur J Cancer. 140:119–129, 2020.
- Ryuma Tokunaga, Joanne Xiu, Richard M Goldberg, Philip A Philip, Andreas Seeber, Francesca Battaglin, Hiroyuki Arai, Jae Ho Lo, Madiha Naseem, Alberto Puccini, Martin D Berger, Shivani Soni, Wu Zhang, Sting Chen, Jimmy J Hwang, Anthony F Shields, John L Marshall, Hideo Baba, W Michael Korn, Heinz-Josef Lenz.

16. Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021.

- J Hepatobiliary Pancreat Sci. 28(1):1–25, 2020.
- Masakazu Yamamoto, Masahiro Yoshida, Junji Furuse, Keiji Sano, Masayuki Ohtsuka, Shingo Yamashita, Toru Beppu, Yukio Iwashita, Keita Wada, Nakajima Eguchi Takako, Katsunori Sakamoto, Koichi Hayano, Yasuhisa Mori, Koji Asai, Ryusei Matsuyama, Tejiro Hirashita, Taizo Hibi, Nozomu Sakai, Tsutomu Tabata, Hisato Kawakami, Hiroyuki Takeda, Takuro Mizukami, Masato Ozaka, Makoto Ueno, Yoichi Naito, Naohiro Okano, Takayuki Ueno, Susumu Hijioka, Satoru Shikata, Tomohiko Ukai, Steven Strasberg, Michael G. Sarr, Palepu Jagannath, Tsann-Long Hwang, Ho-Seong Han, Yoo-Seok Yoon, Hee Jung Wang, Shao-Ciao Luo, Rene Adam, Mariano Gimenez, Olivier Scatton, Do-Youn Oh, Tadahiro Takada.

17. Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.

- Clin Cancer Res. 27(4):1029–1036, 2020.
- Takako Eguchi Nakajima, Shigenori Kadowaki, Keiko Minashi, Tomohiro Nishina, Takeharu Yamanaka, Yuichiro Hayashi, Naoki Izawa, Kei Muro, Shuichi Hironaka, Takeshi Kajiwara, Yutaka Kawakami.

18. Molecular characterization of appendiceal goblet cell carcinoid.

- Molecular Cancer Therapeutics. 19(12):2634–2640, 2020.
- Hiroyuki Arai, Yasmine Baca, Francesca Battaglin, Natsuko Kawanishi, Jingyuan Wang, Shivani Soni, Wu Zhang, Joshua Millstein, Curtis Johnston, Richard M Goldberg, Philip A Philip, Andreas Seeber, Joanne Xiu, Jimmy J Hwang, Anthony F Shields, John L Marshall, W Michael Korn, Heinz-Josef Lenz.

19. RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC.

- Molecular Cancer Therapeutics. 20(6):1153–1160, 2020.
- Hiroyuki Arai, Shu Cao, Francesca Battaglin, Jingyuan Wang, Natsuko Kawanishi, Ryuma Tokunaga, Fotios Loupakis, Sebastian Stintzing, Shivani Soni, Wu Zhang, Christoph Mancao, Bodour Salhia, Shannon M Mumenthaler, Chiara Cremolini, Volker Heinemann, Alfredo Falcone, Joshua Millstein, Heinz-Josef Lenz.

20. Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer.

- Pancreas. 80(1):83–88, 2020.
- Ueno, M.Morinaga, S.Hashimoto, Y.Umemoto, K.Sasahira, N.Saiura, A.Seyama, Y.Honda, G.Ioka, T.Takahashi, H.Miyamoto, A.Nakamori, S.Unno, M.Takadate, T.Mizuno, N.Shimizu, Y.Ueno, H.Sugiyama, M.Fukutomi, A.Shimizu, S.

21. Second-line chemotherapy using taxane in patients with advanced gastric cancer who presented with severe peritoneal metastasis: a multicenter retrospective study.

- Int J Clin Oncol. 26(2):355–363, 2020.
- Hiroyuki Arai, Masahiro Kawahira, Hirofumi Yasui, Toshiki Masuishi, Kei Muro, Takako Eguchi Nakajima.

22. Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer.

- Clin Cancer Res. 27(4):1029–1036, 2021.
- Nakajima TE, Kadowaki S, Minashi K, Nishina T, Yamanaka T, Hayashi Y, Izawa N, Muro K, Hironaka S, Kajiwara T, Kawakami Y.

23. FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study.

- Cancer Chemotherapy and Pharmacology. 87(3):397–404, 2020.
- Umemoto, K.Takahashi, H.Morizane, C.Yamada, I.Shimizu, S.Shioji, K.Yoshida, Y.Motoya, M.Mizuno, N.Kojima, Y.Terashima, T.Uesugi, K.Ueno, M.Furuse, J.Akimoto, T.Ikeda, M.

24. The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer.

- Clinical Cancer Research. 27(11):3234–3242, 2021.
- Hiroyuki Arai, Andrew Elliott, Joanne Xiu, Jingyuan Wang, Francesca Battaglin, Natsuko Kawanishi, Shivani Soni, Wu Zhang, Joshua Millstein, Davendra Sohal, Richard M. Goldberg, Michael J. Hall, Aaron J. Scott, Moh'd Khushman, Jimmy J. Hwang, Emil Lou, Benjamin A. Weinberg, John L. Marshall, Albert C. Lockhart, Phillip Stafford, Jian Zhang, Roberto Moretto, Chiara Cremolini, W. Michael Korn and Heinz-Josef Lenz.

25. Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives.

- Front. Oncol. 11:602194, 2021.
- Hiroyuki Takeda, Yu Sunakawa.

《症例報告》

1. Inferior mesenteric arteriovenous fistula during treatment with bevacizumab in colorectal cancer patient: A case report.

- World Journal of Gastrointestinal Oncology ,12(11): 1364–1371, 2020.
- Ayako Doi, Hiroyuki Takeda, Kumiko Umemoto, Ryosuke Oumi, Shinji Wada, Shingo Hamaguchi, Hidefumi Mimura, Hiroyuki Arai, Yoshiki Horie, Takuro Mizukami, Naoki Izawa, Takashi Ogura, Takako Eguchi Nakajima, Yu Sunakawa.

《その他》

1. REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer.

- Future Oncol. 17(8), 2020.
- Narita Y, Shoji H, Kawai S, Mizukami T, Nakamura M, Moriwaki T, Yamanaka T, Sunakawa Y, Kawakami H, Nishina T, Misumi T, Muro K.

2. Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1–4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy.

- BMJ Open. 10(12): e041737, 2020.
- Hiroko Minatogawa, Naoki Izawa, Takashi Kawaguchi, Tempei Miyaji, Kazuhiro Shimomura, Honda Kazunori, Hirotoshi Iihara, Yasushi Ohno, Yusuke Inada, Hitoshi Arioka, Hajime Morita, Naoya Hida, Mitsuhiro Sugawara, Chikatoshi Katada, Shuichi Nawata, Hiroo Ishida, Ayako Tsuboya, Takashi Tsuda, Takuhiro Yamaguchi, Takako Eguchi Nakajima.